|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02348 DAWNRAYS PHARMA
Nominal 
1.120 -0.020 (-1.754%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 1,230,867 | 16.086% | 1,060,309 | 1,151,145 | 1,277,682 | 1,165,155 |
| Cost of Sales | (618,716) | 28.183% | (482,681) | (509,626) | (504,131) | (483,893) |
| Gross Profit | 612,151 | 5.977% | 577,628 | 641,519 | 773,551 | 681,262 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | (3,696) | (40,933) | (61,905) | (46,418) | |
| Profit / (Loss) before Taxation | 249,613 | -60.811% | 636,949 | 414,057 | 438,408 | 439,323 | |
| Taxation | (38,506) | -48.096% | (74,187) | (91,390) | (82,557) | (85,160) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 2,864 | 31.497% | 2,178 | 3,333 | 2,206 | 4,012 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 213,971 | -62.125% | 564,940 | 326,000 | 358,057 | 358,175 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (29,765) | -9.295% | (32,815) | (24,938) | (19,004) | (19,171) |
| Depreciation & Amortisation | 90,956 | -14.694% | 106,623 | 83,893 | 66,410 | 57,545 |
| Directors' Emoluments | -- | -- | 3,031 | 2,973 | 3,089 | 9,667 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 14.000 | -63.158% | 38.000 | 21.740 | 23.890 | 23.920 |
| DPS (cts) | 5.548 | -- | 8.798 | 7.262 | 7.666 | 6.513 |
| Dividend Payout Ratio (%) | 39.629% | -- | 23.153% | 33.405% | 32.087% | 27.226% |
| Cash flow per share ($) | -- | -- | 0.146 | 0.226 | 0.290 | 0.263 |
| NBV per share ($) | 2.252 | -- | 2.213 | 1.903 | 1.763 | 1.589 |
| Remarks: | Real time quote last updated: 10/04/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 213,971 |
| %Change | -62.125% |
| EPS / (LPS) | RMB 0.140 |
| NBV Per Share (¥) | RMB 2.252 |